The role of FOXM1 and PD-L1 in malignant peripheral nerve sheath tumor resistance

A new mini review was published in Oncotarget’s Volume 15 on September 30, 2024, entitled, “Linking FOXM1 and PD-L1 to CDK4/6-MEK targeted therapy resistance in malignant peripheral nerve sheath tumors.”

Seaport emerges after $100m raise with ex-Karuna team at helm – Pharmaceutical Technology

Share this article Bristol-Myers Squibb acquired Karuna for $14bn in late 2023. Image credit: Shutterstock/Mr.Che. Seaport Therapeutics has entered the neuropsychiatry treatment space after emerging

April 9, 2024

FDA Greenlights New Myasthenia Gravis Drug

The FDA approved rozanolixizumab-noli (Rystiggo), a neonatal Fc receptor blocker, to treat adults with generalized myasthenia gravis (gMG), UCB announced Tuesday. The drug is the

June 28, 2023

CDC Prepping for ‘Possibility of Increased Risk to Human Health’ From Bird Flu

The CDC is preparing for the possibility of H5N1 posing an increased risk to human health, even though that current risk remains low, the agency

May 25, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.